Published in HIV Med on August 19, 2010
How Next-Generation Sequencing and Multiscale Data Analysis Will Transform Infectious Disease Management. Clin Infect Dis (2015) 2.12
Detection of cytomegalovirus drug resistance mutations by next-generation sequencing. J Clin Microbiol (2013) 1.04
Computational models can predict response to HIV therapy without a genotype and may reduce treatment failure in different resource-limited settings. J Antimicrob Chemother (2013) 0.91
Can linear regression modeling help clinicians in the interpretation of genotypic resistance data? An application to derive a lopinavir-score. PLoS One (2011) 0.81
An update to the HIV-TRePS system: the development of new computational models that do not require a genotype to predict HIV treatment outcomes. J Antimicrob Chemother (2013) 0.81
Scoring methods for building genotypic scores: an application to didanosine resistance in a large derivation set. PLoS One (2013) 0.80
The individualized genetic barrier predicts treatment response in a large cohort of HIV-1 infected patients. PLoS Comput Biol (2013) 0.77
Determination of Phenotypic Resistance Cutoffs from Routine Clinical Data. J Acquir Immune Defic Syndr (2016) 0.75
Integrated multisystem analysis in a mental health and criminal justice ecosystem. Health Justice (2017) 0.75
Integrated multisystem analysis in a mental health and criminal justice ecosystem. AMIA Annu Symp Proc (2014) 0.75
Using drug exposure for predicting drug resistance - A data-driven genotypic interpretation tool. PLoS One (2017) 0.75
Combining Kernel and Model Based Learning for HIV Therapy Selection. AMIA Jt Summits Transl Sci Proc (2017) 0.75
Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. The Swedish Study Group. Lancet (1998) 14.31
The introduction of jet injection mass vaccination into the national smallpox eradication program of Brazil. Trop Geogr Med (1971) 11.37
DNA diagnostics--molecular techniques and automation. Science (1988) 8.85
Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomised non-inferiority trial. Lancet (2009) 7.96
Exogenous reinfection with multidrug-resistant Mycobacterium tuberculosis in patients with advanced HIV infection. N Engl J Med (1993) 7.85
A ligase-mediated gene detection technique. Science (1988) 7.61
A fast flexible docking method using an incremental construction algorithm. J Mol Biol (1996) 7.33
Public-health impact of outdoor and traffic-related air pollution: a European assessment. Lancet (2000) 6.95
Genome sequence of the plant pathogen Ralstonia solanacearum. Nature (2002) 6.23
Ordered accumulation of mutations in HIV protease confers resistance to ritonavir. Nat Med (1996) 6.14
Fifth mutation in human immunodeficiency virus type 1 reverse transcriptase contributes to the development of high-level resistance to zidovudine. Proc Natl Acad Sci U S A (1992) 5.19
Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy. Science (1995) 4.98
Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomised controlled trial. Lancet (1999) 4.68
Neutralizing antibody responses in acute human immunodeficiency virus type 1 subtype C infection. J Virol (2007) 4.13
Reduced replication of 3TC-resistant HIV-1 variants in primary cells due to a processivity defect of the reverse transcriptase enzyme. EMBO J (1996) 3.92
Increased cell division but not thymic dysfunction rapidly affects the T-cell receptor excision circle content of the naive T cell population in HIV-1 infection. Nat Med (2000) 3.70
Failure of zidovudine prophylaxis after accidental exposure to HIV-1. N Engl J Med (1990) 3.61
Increased fitness of drug resistant HIV-1 protease as a result of acquisition of compensatory mutations during suboptimal therapy. AIDS (1999) 3.51
Persistence of nevirapine-resistant HIV-1 in women after single-dose nevirapine therapy for prevention of maternal-to-fetal HIV-1 transmission. Proc Natl Acad Sci U S A (2006) 3.26
Multidrug-resistant human immunodeficiency virus type 1 strains resulting from combination antiretroviral therapy. J Virol (1996) 3.21
Regular physical exercise corrects endothelial dysfunction and improves exercise capacity in patients with chronic heart failure. Circulation (1998) 2.90
Automated DNA diagnostics using an ELISA-based oligonucleotide ligation assay. Proc Natl Acad Sci U S A (1990) 2.88
A 6-basepair insert in the reverse transcriptase gene of human immunodeficiency virus type 1 confers resistance to multiple nucleoside inhibitors. J Clin Invest (1998) 2.88
Antibody response in primary human immunodeficiency virus infection. Lancet (1987) 2.69
Late presentation of HIV infection: a consensus definition. HIV Med (2011) 2.67
Improved cervical smear assessment using antibodies against proteins that regulate DNA replication. Proc Natl Acad Sci U S A (1998) 2.61
Subtype-specific problems with quantification of plasma HIV-1 RNA. AIDS (1997) 2.60
Autoimmune thrombocytopenic purpura in homosexual men. Ann Intern Med (1982) 2.57
Detection of IgG antibodies to lymphadenopathy-associated virus in patients with AIDS or lymphadenopathy syndrome. Lancet (1984) 2.56
Genetic variants of HIV-1 in Thailand. AIDS Res Hum Retroviruses (1992) 2.52
European guidelines on the clinical management of HIV-1 tropism testing. Lancet Infect Dis (2011) 2.47
Centralization: a new method for the normalization of gene expression data. Bioinformatics (2001) 2.47
Human immunodeficiency virus type 1 (HIV-1) plasma load discrepancies between the Roche COBAS AMPLICOR HIV-1 MONITOR Version 1.5 and the Roche COBAS AmpliPrep/COBAS TaqMan HIV-1 assays. J Clin Microbiol (2007) 2.40
HIV-1 genotypic resistance patterns predict response to saquinavir-ritonavir therapy in patients in whom previous protease inhibitor therapy had failed. Ann Intern Med (1999) 2.36
Sensitive procedure for the amplification of HIV-1 RNA using a combined reverse-transcription and amplification reaction. Biotechniques (1995) 2.36
Limited humoral immunity in hepatitis C virus infection. Gastroenterology (1999) 2.31
Analysis of gene expression data with pathway scores. Proc Int Conf Intell Syst Mol Biol (2000) 2.30
Evaluation of the FLEXX incremental construction algorithm for protein-ligand docking. Proteins (1999) 2.30
Interferon-alpha and tumor necrosis factor-alpha in serum of patients in various stages of HIV-1 infection. AIDS Res Hum Retroviruses (1991) 2.29
Engineering support vector machine kernels that recognize translation initiation sites. Bioinformatics (2000) 2.29
Loss of memory (CD27) B lymphocytes in HIV-1 infection. AIDS (2001) 2.28
A mutation in human immunodeficiency virus reverse transcriptase and decline in CD4 lymphocyte numbers in long-term zidovudine recipients. J Infect Dis (1993) 2.28
HIV in pregnant women and their offspring: evidence for late transmission. Lancet (1991) 2.27
Tuberculosis control and molecular epidemiology in a South African gold-mining community. Lancet (2000) 2.26
Lyme borreliosis: clinical case definitions for diagnosis and management in Europe. Clin Microbiol Infect (2011) 2.23
A highly divergent picornavirus in a marine mammal. J Virol (2007) 2.23
Stochastic processes strongly influence HIV-1 evolution during suboptimal protease-inhibitor therapy. Proc Natl Acad Sci U S A (1998) 2.23
Assessment of deaths attributable to air pollution: should we use risk estimates based on time series or on cohort studies? Am J Epidemiol (2001) 2.19
Tolerance and contact sensitivity to DNFB in mice. I. In vivo detection by ear swelling and correlation with in vitro cell stimulation. J Immunol (1974) 2.18
Zidovudine treatment results in the selection of human immunodeficiency virus type 1 variants whose genotypes confer increasing levels of drug resistance. J Gen Virol (1994) 2.18
env sequences of simian immunodeficiency viruses from chimpanzees in Cameroon are strongly related to those of human immunodeficiency virus group N from the same geographic area. J Virol (2000) 2.17
Outcome of lamivudine resistant hepatitis B virus infection in the liver transplant recipient. Gut (2000) 2.16
Technetium-99m hexakis 2-methoxyisobutyl isonitrile: human biodistribution, dosimetry, safety, and preliminary comparison to thallium-201 for myocardial perfusion imaging. J Nucl Med (1989) 2.15
Multiple drug rescue therapy for HIV-infected individuals with prior virologic failure to multiple regimens. AIDS (2001) 2.15
Human Immunodeficiency Virus Reverse Transcriptase and Protease Sequence Database: an expanded data model integrating natural language text and sequence analysis programs. Nucleic Acids Res (2001) 2.13
Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration. Cancer Res (2001) 2.11
Evolution of lamivudine resistance in human immunodeficiency virus type 1-infected individuals: the relative roles of drift and selection. J Virol (2000) 2.11
Diagnosis of primary HIV-1 infection and duration of follow-up after HIV exposure. Karolinska Institute Primary HIV Infection Study Group. AIDS (2000) 2.08
Maternal vitamin D status in pregnancy and offspring bone development: the unmet needs of vitamin D era. Osteoporos Int (2013) 2.07
A superfamily of proteins involved in different secretion pathways in gram-negative bacteria: modular structure and specificity of the N-terminal domain. Mol Gen Genet (1994) 2.07
FlexE: efficient molecular docking considering protein structure variations. J Mol Biol (2001) 2.05
Preclinical evaluation of HBY 097, a new nonnucleoside reverse transcriptase inhibitor of human immunodeficiency virus type 1 replication. Antimicrob Agents Chemother (1995) 2.04
Human immunodeficiency virus type 1 protease cleavage site mutations associated with protease inhibitor cross-resistance selected by indinavir, ritonavir, and/or saquinavir. J Virol (2001) 2.04
Characteristics of the specific cell-mediated immune response in human immunodeficiency virus infection. J Virol (1987) 1.99
Gene for familial psoriasis susceptibility mapped to the distal end of human chromosome 17q. Science (1994) 1.99
Development and clinical significance of the musculus dorsoepitrochlearis in men. Clin Anat (2009) 1.98
Human immunodeficiency virus type 1 reverse-transcriptase and protease subtypes: classification, amino acid mutation patterns, and prevalence in a northern California clinic-based population. J Infect Dis (2001) 1.97
Unified nomenclature for broadly conserved hrp genes of phytopathogenic bacteria. Mol Microbiol (1996) 1.95
British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy. HIV Med (2003) 1.94
Dengue fever in a Puerto Rican community. Am J Epidemiol (1967) 1.93
A novel polymorphism at codon 333 of human immunodeficiency virus type 1 reverse transcriptase can facilitate dual resistance to zidovudine and L-2',3'-dideoxy-3'-thiacytidine. J Virol (1998) 1.92
Full-length sequence of an ethiopian human immunodeficiency virus type 1 (HIV-1) isolate of genetic subtype C. AIDS Res Hum Retroviruses (1996) 1.92
Initial appearance of the 184Ile variant in lamivudine-treated patients is caused by the mutational bias of human immunodeficiency virus type 1 reverse transcriptase. J Virol (1997) 1.91
Findings in a fox rescued from hounds. Vet Rec (1999) 1.90
T- and B-cell responses to different hepatitis C virus antigens in patients with chronic hepatitis C infection and in healthy anti-hepatitis C virus--positive blood donors without viremia. Hepatology (1996) 1.88
Estimating relative fitness in viral competition experiments. J Virol (2000) 1.87
Nevirapine-associated toxicity in HIV-infected Thai men and women, including pregnant women. HIV Med (2007) 1.83
Clinical practice. Noninvasive tests in patients with stable coronary artery disease. N Engl J Med (2001) 1.82
PopA1, a protein which induces a hypersensitivity-like response on specific Petunia genotypes, is secreted via the Hrp pathway of Pseudomonas solanacearum. EMBO J (1994) 1.79
Determinants of survival in progressive multifocal leukoencephalopathy. Neurology (2009) 1.77
Epidemic intelligence: a new framework for strengthening disease surveillance in Europe. Euro Surveill (2006) 1.75
Viral dynamics in primary HIV-1 infection. Karolinska Institutet Primary HIV Infection Study Group. AIDS (2000) 1.75
Multicenter comparison of three commercial methods for quantification of human immunodeficiency virus type 1 RNA in plasma. J Clin Microbiol (1996) 1.75
Resistance-associated mutations in the human immunodeficiency virus type 1 subtype c protease gene from treated and untreated patients in the United Kingdom. J Clin Microbiol (2001) 1.75
hrp genes of Pseudomonas solanacearum are homologous to pathogenicity determinants of animal pathogenic bacteria and are conserved among plant pathogenic bacteria. Mol Plant Microbe Interact (1993) 1.75
The novel activation of ABL by fusion to an ets-related gene, TEL. Cancer Res (1995) 1.73
Incidence and morbidity of cytomegaloviral infection in patients with mediastinitis following cardiac surgery. Chest (1990) 1.72
High sustained response rate and clearance of viremia in chronic hepatitis C after treatment with interferon-alpha 2b for 60 weeks. Hepatology (1994) 1.71
Explaining variability in the relationship between antiretroviral adherence and HIV mutation accumulation. J Antimicrob Chemother (2006) 1.70
Immunologic study of human encephalitic and paralytic rabies. Preliminary report of 16 patients. Am J Med (1988) 1.69
Phenotypic characteristics of human immunodeficiency virus type 1 subtype C isolates of Ethiopian AIDS patients. AIDS Res Hum Retroviruses (1999) 1.69
Increased frequency of the HLA-DR15 (B1*15011) allele in German patients with self-limited hepatitis C virus infection. Eur J Clin Invest (1999) 1.68